PEAK study1: OS in patients with left-sided primary tumours
Adapted from Boeckx et al1
PEAK is a phase 2, multicentre, randomised study evaluating Vectibix® + FOLFOX and bevacizumab + FOLFOX in patients with previously untreated wild-type KRAS (exon 2) mCRC.1 No formal hypothesis testing was planned.1
- Boeckx N, et al. Primary tumor sidedness has an impact on prognosis and treatment outcome in metastatic colorectal cancer: results from two randomized first-line panitumumab studies. Ann Oncol. 2017. doi: 10.1093/annonc/mdx119.
EGFRi offer significant objective response rates for patients with right-sided primary tumours1
ORR in predictive analyses
Between HR interaction heterogeneity: P = 0.77
Adapted from Arnold et al.1
- Arnold D, et al. Prognostic and predictive value of primary tumour side in patients with RAS wild-type metastatic colorectal cancer treated with chemotherapy and EGFR directed antibodies in six randomised trials. Ann Oncol. 2017. doi: 10.1093/annonc/mdx175.